| Disease | IN THIS PILOT STUDY NINE PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA WERE GIVEN COMBINATION CHEMOTHERAPY CONSISTING OF TENIPOSIDE (100 G/SQ.M.,DAYS 1-3), DOXORUBICIN (IV, 30 MG/SQ.M. DAYS 1-3), CYCLOPHOSPHAMIDE (300 MG/SQ.M, IV DAYS 1-3, AND DAYS4-7,
PREDNISOLONE (PO, 100 MG/SQ.M. DAYS 4-10), METHOTREXATE (100 MG/SQ.M., IV, DAY 8), LEUCOVORIN (30 MG, IM, 4 TIMES AT 6 HR INTERVALS AFTER METHOTREXATE), AND VINCRISTINE (1.4 MG/SQ.M., IV, DAYS 8, 15 AND 22 TO A MAXIMUM DOSE OF 2 MG).
PERIPHERAL NEUROTOXICITY WAS SEVERE IN THESE CASES AND COULD BE DUE TO THE SEQUENTIAL USE OF VINCRISTINE AND TENIPOSIDE.
CLINICAL SIGNS OF NEUROPATHY INCLUDED PARESTHESIA, DEEP TENDON REFLEXES ABSENT OR REDUCED IN THE ACHILLES TENDON, ARMS AND/OR LEGS, BILATERAL FOOT DROP AND HAND WEAKNESS AND REDUCED SENSATION IN THE FINGERS. |